Clinical Trial Update: Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial compares Izalontamab Brengitecan (BMS-986507) against platinum-pemetrexed for EGFR-mutated non-small cell lung cancer after failure o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Izalontamab Brengitecan
• Pemetrexed (pemetrexed)
• Platinum-based chemotherapy (cisplatin or carboplatin) + pemetrexed

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING